Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
Author:
Affiliation:
1. Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b00261
Reference110 articles.
1. Parkinson's disease: clinical features and diagnosis
2. Stages in the development of Parkinson’s disease-related pathology
3. Neurobiology and treatment of Parkinson's disease
4. Human genetics as a foundation for innovative drug development
5. Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson’s disease;Bioorganic Chemistry;2024-02
2. Structural insight into G2019S mutated LRRK2 kinase and brain-penetrant type I inhibitor complex: a molecular dynamics approach;Journal of Biomolecular Structure and Dynamics;2023-09-13
3. Mutant LRRK2 exacerbates immune response and neurodegeneration in a chronic model of experimental colitis;Acta Neuropathologica;2023-06-08
4. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease;Journal of Medicinal Chemistry;2022-12-07
5. A Potential Strategy for Treatment of Neurodegenerative Disorders by Regulation of Adult Hippocampal Neurogenesis in Human Brain;Current Medicinal Chemistry;2022-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3